Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Capital Reinvestment Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Capital Reinvestment Ratio of 0.40x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥61.35 Million) in capital expenditures (CN¥24.30 Million). See Chengdu Easton Biopharmaceuticals Co Ltd (688513) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Chengdu Easton Biopharmaceuticals Co Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks Chengdu Easton Biopharmaceuticals Co Ltd's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. For live market cap and broader valuation context, see Chengdu Easton Biopharmaceuticals Co Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.33x | CN¥264.94 Million | CN¥86.28 Million | ▼ -27.0% |
| 2024 | 0.45x | CN¥263.24 Million | CN¥117.42 Million | ▼ -29.9% |
| 2023 | 0.64x | CN¥275.25 Million | CN¥175.26 Million | ▼ -71.5% |
| 2022 | 2.23x | CN¥151.94 Million | CN¥339.33 Million | ▲ +28.6% |
| 2021 | 1.74x | CN¥147.60 Million | CN¥256.29 Million | ▲ +36.7% |
| 2020 | 1.27x | CN¥156.52 Million | CN¥198.81 Million | ▲ +88.8% |
| 2019 | 0.67x | CN¥141.83 Million | CN¥95.41 Million | ▲ +46.4% |
| 2018 | 0.46x | CN¥166.79 Million | CN¥76.63 Million | ▲ +71.0% |
| 2017 | 0.27x | CN¥85.70 Million | CN¥23.02 Million | ▲ +59.8% |
| 2016 | 0.17x | CN¥106.06 Million | CN¥17.83 Million | ▼ -76.0% |
| 2015 | 0.70x | CN¥50.57 Million | CN¥35.43 Million | ▲ +48.5% |
| 2014 | 0.47x | CN¥46.71 Million | CN¥22.04 Million | ▼ -82.6% |
| 2013 | 2.71x | CN¥28.12 Million | CN¥76.11 Million | — |